

**Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial**

*Belperio John A.<sup>1</sup>, Nguyen Tuan<sup>2</sup>, Lombardi David A.<sup>2</sup>, Boguş Maxim<sup>34</sup>, Moskalenko Valentyn<sup>56</sup>, Singh Dave<sup>7</sup>, Haumann Brett<sup>8</sup>, Bourdet David L.<sup>2</sup>, Kaufman Elad<sup>2</sup>, Pfeifer Nathan D.<sup>2</sup>, Thompson Corbin G.<sup>2</sup>, Woo Jacky<sup>2</sup>, Moran Edmund J.<sup>2</sup>, Saggur Rajeev<sup>2</sup>*

<sup>1</sup> Ronald Reagan UCLA Medical Center, Los Angeles,

<sup>2</sup> Theravance Biopharma Inc, South San Francisco,

<sup>3</sup> F.C.E. ARENSIA Exploratory Medicine,

<sup>4</sup> Timofei Moşneaga Republican Clinical Hospital,

<sup>5</sup> Kyiv City Clinical Hospital #12,

<sup>6</sup> Brovary multidisciplinary clinical hospital,

<sup>7</sup> University of Manchester,

<sup>8</sup> Theravance Biopharma UK Limited, London

**BMJ Open Respiratory Research**

Vol. 10, / 2023 / ISSN 2052-4439

Disponibil online 15 August, 2023. Descarcări-1. Vizualizări-153



Copyright © 2011-2024 Instrumentul Bibliometric Național.

Institutul de Dezvoltare a Societății Informaționale.

Actualizat: 04.07.2024, accesat: 04.07.2024

Disponibil: <https://ibn.idsi.md>

